source
- FDA delays decision on Belite Bio's Stargardt disease drug to May 12The FDA announced it will extend its review of Belite Bio's new drug application for tinlarebant, an oral small-molecule intended to treat Stargardt disease type 1, moving the PDUFA action date fro…
- ‘It’s a very healthy sector’: Biopharma gathers in London as M&A shines and China clouds loomAs the grand hotels and cosy cafes filled with biopharma executives and investors for London Life Sciences Week, the weather was as temperamental as any other English November.